Author's response to reviews

Title: Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial

Authors:

Felix Espinoza (joelpaq@ibw.com.ni)
Miguel Tregnaghi (miguelt@millicom.com.ar)
Angela Gentile (angelagentile@fibertel.com.ar)
Katia Arbaca (katia@med.puc.cl)
Javier Casellas (javier.m.casellas@gsk.com)
Alix Collard (alix.collard@gskbio.com)
Inge Lefevre (inge.lefevre@gskbio.com)
Jeanne Jacquet (jeanne.jacquet@gskbio.com)

Version: 7 Date: 21 September 2010

Author's response to reviews: see over
Dear Production Team,

Thank-you for accepting our manuscript (1879670436360575 - Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial).

We have revised the document as detailed below:

Yours sincerely

Dr Jeanne-Marie Jacquet
**Major revisions (we require the author to make these changes)**

Author list: the list of authors in the manuscript should be written exactly as they are in the submission system, both in style and order. The preferred style is ‘First name Initial Last name’ (e.g. Joe F Bloggs). Currently they do not match.

*Revised in web page*

Abstract: the trial registration number must be mentioned in the abstract. The last section of the abstract must be titled Trial Registration, and must list the trial registry and the unique identifying number. Please note that there must be no space between the letters and numbers of the trial registration number (e.g. ISRCTN12345678). Please ensure that you have also updated the abstract in the submission system to ensure it remains identical to the manuscript.

*Revised in document on abstract page; also updated on submission system*

Tables: we are unable to display shading and colours within the tables. Can we therefore ask you to use another method of highlighting the shaded text e.g. by making it bold.

*Shading removed from tables*

**Minor revisions**

Affiliations: Please remember to include the city in the affiliation details.

*Revised in document on title page*

Title page: Please display the authors’ affiliations and email addresses in separate sections on the title page.

*Revised in document on title page*

Structure: Please insert a heading titled ‘Conclusions’ after the discussion.

*Revised in document*

References: the reference list should contain up to 30 authors’ names for each citation. The term ‘et al.’ should not be used if there are fewer than 30 authors.

*Revised in document*

Table 1: Please remove the repeated column headings from this table

*Revised in document*
Figures: The image file should not include the title (e.g. Figure 1... etc.) or figure number. The legend and title should be part of the manuscript file after the reference list. The figures are numbered automatically in the order in which they are uploaded.

The figure includes titles of ‘primary vaccination study’ and ‘Booster study’; it is important to retain these titles to differentiate between the two trials.

Typography: Please take this opportunity to check your manuscript for any typographical errors and to make any final corrections or revisions. This is the final proofing stage for your manuscript, and you will not be able to make any changes after acceptance.

All checked